Application of proteomics in asthma research

Expert Review of Proteomics

Volumn 8, Issue 2, 2011, Pages 221-230

  Park, Choon Sik ^a   Rhim, Taiyoun ^b  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

asthma; BAL fluid; plasma; proteomics

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CANCER GROWTH FACTOR; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 12; INTERLEUKIN 4; OMALIZUMAB; POLLEN ANTIGEN; SHORT ACTING DRUG; STEROID; VOLATILE ORGANIC COMPOUND;

ASTHMA; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; CYTOKINE RESPONSE; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DYSPNEA; EARLY INTERVENTION; HOUSE DUST ALLERGY; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MEDICAL RESEARCH; MOLECULAR MODEL; NONHUMAN; PEAK EXPIRATORY FLOW; PREVALENCE; PROTEOMICS; RESPIRATORY AIRFLOW; REVIEW; SKIN TEST; SPUTUM; TREATMENT INDICATION; WHEEZING;

ANIMALS; ASTHMA; BIOLOGICAL MARKERS; HUMANS; PROTEOMICS;

EID: 79955066779     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.11.4     Document Type: Review

References (88)

1. Lee JY, Park SW, Chang HK et al. A disintegrin and metalloproteinase 33 protein in patients with asthma: relevance to airflow limitation. Am. J. Respir. Crit. Care Med. 173(7), 729-735 (2006).
2. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 22, 789-815 (2004). (Pubitemid 38680442)
3. Sengler C, Lau S, Wahn U et al. Interactions between genes and environmental factors in asthma and atopy: new developments. Respir. Res. 3, 7 (2002).
4. Anderson HR, Ruggles R, Strachan DP et al. Trends in prevalence of symptoms of asthma, hay fever, and eczema in 12-14 year olds in the British Isles, 1995-2002: questionnaire survey. BMJ 328, 1052-1053 (2004). (Pubitemid 38580829)
5. Joint Health Surveys Unit. Health Survey for England. Stationery Office, London, UK (2002).
6. Robertson CF, Roberts MF, Kappers JH. Asthma prevalence in Melbourne schoolchildren: have we reached the peak? Med. J. Aust. 180, 273-276 (2004). (Pubitemid 38372231)
7. Anderson HR. Prevalence of asthma. BMJ 330(7499), 1037-1038 (2005). (Pubitemid 40646549)
8. Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr. Opin. Allergy Clin. Immunol. 7(1), 43-50 (2007). (Pubitemid 46095885)
9. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 26, 368(9537), 804-813 (2006). (Pubitemid 44279058)
10. Shin EK, Lee SH, Cho SH et al. Association between colony-stimulating factor 1 receptor gene polymorphisms and asthma risk. Hum. Genet. 128(3), 293-302 (2010).
11. Kamada AK, Szefler SJ, Martin RJ et al. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am. J. Respir. Crit. Care Med. 53, 1739-1748 (1996). (Pubitemid 26187895)
12. O'Byrne PM, Pedersen S, Busse WW et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. START Investigators Group. Chest 129(6), 1478-1485 (2006). (Pubitemid 43894975)
13. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. NIH publication no. 02-3659. National Institutes of Health National Heart, Lung and Blood Institute, Bethesda, MD, USA (2002).
14. Toogood JH. High-dose inhaled steroid therapy for asthma. J. Allergy Clin. Immunol. 83, 528-536 (1989). (Pubitemid 19087923)
15. Szefler SJ, Martin RJ, King TS et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 109(3), 410-418 (2002). (Pubitemid 34234189)
16. Jang AS, Lee J, Park SW et al. Factors influencing the responsiveness to high dose inhaled glucocorticoids in patients with asthma. Chest 128, 1140-1145 (2005). (Pubitemid 41324388)
17. Pignatti PF. Trends in pharmacogenomics of drugs used in the treatment of asthma. Pharmacol. Res. 49, 343-349 (2004). (Pubitemid 38175331)
18. Noonan MJ, Chervinsky P, Brandon M et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur. Respir. J. 11(6), 1232-1239 (1998). (Pubitemid 28298582)
19. Reiss TF, Chervinsky P, Dockhorn RJ et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 158(11), 1213-1220 (1998).
20. Leff JA, Busse WW, Pearlman D et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise induced bronchoconstriction. N. Engl. J. Med. 339(3), 147-152 (1998). (Pubitemid 28328478)
21. Dahlen B, Nizankowska E, Szczeklik A et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care Med. 157, 1187-1194 (1998).
22. Hall IP. Genetics and pulmonary medicine 8: asthma. Thorax 54(1), 65-69 (1999).
23. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun. 7(2), 95-100 (2006). (Pubitemid 43336051)
24. Boezen HM. Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? Proc. Am. Thorac. Soc. 6(8), 701-703 (2009).
25. Moffatt MF, Kabesch M, Liang L et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448, 470-473 (2007). (Pubitemid 47123521)
26. Gudbjartsson DF, Bjornsdottir US, Halapi E et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342-347 (2009).
27. Carriere V, Roussel L, Ortega N et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl Acad. Sci. USA 104, 282-287 (2007). (Pubitemid 46068023)
28. Nagy SM. Clinical and allergic evaluation of the patient with bronchial asthma. In:Bronchial Asthma: Principles of Diagnosis and Treatment (4th Edition). Gershwin MF, Albertson TE (Eds). Humana Press, NJ, USA, 75-93 (2001).
29. von Mutius E, Martinez FD, Fritzsch C et al. Prevalence of asthma and atopy in two areas of West and East Germany. Am. J. Respir. Crit. Care Med. 149, 358-364 (1994). (Pubitemid 24068980)
30. Leung R, Ho P. Asthma, allergy, and atopy in three South-east Asian populations. Thorax 49, 1205-1210 (1994).
31. Becker AB. Primary prevention of allergy and asthma is possible. Clin. Rev. Allergy Immunol. 28(1), 5-16 (2005). (Pubitemid 41272848)
32. Bortenschlager S, Bortenschlager I. Altering airborne pollen concentrations due to the global warming. A comparative analysis of airborne pollen records from Innsbruck and Obergurgl (Austria) for the period 1980-2001. Grana 44(3), 172-180 (2005). (Pubitemid 41585069)
33. Frei T, Gassner E. Climate change and its impact on birch pollen quantities and the start of the pollen season an example from Switzerland for the period 1969-2006. Int. J. Biometeorol. 52(7), 667-674 (2008).
34. Kishikawa R, Koto E, Iwanaga T et al. [Long-term study of airborne allergic pollen count, C. Japonica and cupressaceae in Japan]. Arerugi 50(4), 369-378(2001).
35. Fujimura T, Shigeta S, Kawamoto S et al. Two-dimensional IgE-binding spectrum of Japanese cedar (Cryptomeria japonica) pollen allergens. Int. Arch. Allergy Immunol. 133(2), 125-135 (2004). (Pubitemid 38314644)
36. Batard T, Didierlaurent A, Chabre H et al. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int. Arch. Allergy Immunol. 136(3), 239-249 (2005). (Pubitemid 40529195)
37. Luengo O, Molla R, Gamez C et al. Allergenicity and cross-reactivity of Senecio pollen: identification of novel allergens using the immunoproteomics approach. Clin. Exp. Allergy 38(6), 1048-1060 (2008). (Pubitemid 351725858)
38. Luoto S, Lambert W, Blomqvist A et al. The identification of allergen proteins in sugar beet (Beta vulgaris) pollen causing occupational allergy in greenhouses. Clin. Mol. Allergy 11, 6-7 (2008).
39. Vliagoftis H, Forsythe P. Should we target allergen protease activity to decrease the burden of allergic airway inflammation? Inflamm. Allergy Drug Targets 7(4), 288-295 (2008).
40. Grobe K, Becker WM, Schlaak M, Petersen A. Grass group I allergens (b-expansins) are novel, papain-related proteinases. Eur. J. Biochem. 263, 33-40 (1999). (Pubitemid 29313835)
41. Grobe K, Poppelmann M, Becker WM, Petersen A. Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases. Eur. J. Biochem. 269, 2083-2092 (2002). (Pubitemid 34437850)
42. Raftery MJ, Saldanha RG, Geczy CL, Kumar RK. Mass spectrometric analysis of electrophoretically separated allergens and proteases in grass pollen diffusates Respir. Res. 4, 10 (2003).
43. Sheoran IS, Ross AR, Olson DJ, Sawhney VK. Proteomic analysis of tomato (Lycopersicon esculentum) pollen. J. Exp. Bot. 58(13), 3525-3535 (2007). (Pubitemid 350232990)
44. Alm R, Ekefjärd A, Krogh M, Häkkinen J, Emanuelsson C. Proteomic variation is as large within as between strawberry varieties. J. Proteome Res. 6(8), 3011-3020 (2007). (Pubitemid 47310186)
45. Rosengren AT, Nyman TA, Lahesmaa R. Proteome profiling of interleukin-12 treated human T helper cells. Proteomics 5(12), 3137-3141 (2005). (Pubitemid 41176481)
46. Altraja S, Jaama J, Valk E, Altraja A. Changes in the proteome of human bronchial epithelial cells following stimulation with leucotriene E4 and transforming growth factor-b1. Respirology 14(1), 39-45 (2009).
47. Candiano G, Bruschi M, Pedemonte N et al. Gelsolin secretion in interleukin-4- treated bronchial epithelia and in asthmatic airways. Am. J. Respir. Crit. Care Med. 172(9), 1090-1096 (2005). (Pubitemid 43066643)
48. Weisel CP. Assessing exposure to air toxics relative to asthma. Environ. Health Perspect. 110(Suppl. 4), 527-537 (2002).
49. Pope CA, Kanner RE. Acute effects of PM10 pollution on pulmonary function of smokers with mild to moderate chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 147, 1336-1340 (1993). (Pubitemid 23160524)
50. Xiao GG, Wang M, Li N, Loo JA, Nel AE. Use of proteomics to demonstrate a hierarchical oxidative stress response to diesel exhaust particle chemicals in a macrophage cell line. J. Biol. Chem. 278(50), 50781-50790 (2003). (Pubitemid 37548927)
51. Wang M, Xiao GG, Li N et al. Use of a fluorescent phosphoprotein dye to characterize oxidative stress-induced signaling pathway components in macrophage and epithelial cultures exposed to diesel exhaust particle chemicals. Electrophoresis 26(11), 2092-2108 (2005). (Pubitemid 40852641)
52. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 311(5761), 622-627 (2006). (Pubitemid 43191298)
53. Cha MH, Rhim T, Kim KH et al. Proteomic identification of macrophage migration-inhibitory factor upon exposure to TiO2 particles. Mol. Cell Proteomics 6(1), 56-63 (2007). (Pubitemid 46152691)
54. Mörbt N, Mögel I, Kalkhof S et al. Proteome changes in human bronchoalveolar cells following styrene exposure indicate involvement of oxidative stress in the molecular-response mechanism. Proteomics 9(21), 4920-4933 (2009).
55. Ahn M, Park BJ, Kwon JH et al. Asp-Tyr-Leu-Lys tetrapeptide inhibits airway inflammation in toluene-2,4- diisocyanate-induced asthma mice. Clin. Exp. Allergy 38(6),1025-1032 (2008). (Pubitemid 351725850)
56. Houtman R, Krijgsveld J, Kool M et al. Lung proteome alterations in a mouse model for nonallergic asthma. Proteomics 3(10), 2008-2018 (2003). (Pubitemid 37309352)
57. Jeong H, Rhim T, Ahn MH et al. Proteomic analysis of differently expressed proteins in a mouse model for allergic asthma. J. Korean Med. Sci. 20(4), 579-585 (2005). (Pubitemid 41265134)
58. Zhao J, Zhu H, Wong CH, Leung KY, Wong WS. Increased lungkine and chitinase levels in allergic airway inflammation: a proteomics approach. Proteomics 5(11), 2799-2807 (2005). (Pubitemid 41059758)
59. Calvo FQ, Fillet M, de Seny D et al. Biomarker discovery in asthma-related inflammation and remodeling. Proteomics 9(8), 2163-2170 (2009).
60. Roh GS, Shin Y, Seo SW et al. Proteome analysis of differential protein expression in allergen-induced asthmatic mice lung after dexamethasone treatment. Proteomics 4(11), 3318-3327 (2004). (Pubitemid 39525279)
61. Liu H, Zhou LF, Zhang Q et al. Increased RhoGDI2 and peroxiredoxin 5 levels in asthmatic murine model of b2-adrenoceptor desensitization: a proteomics approach. Chin. Med. J. (Engl.) 121(4), 355-362 (2008). (Pubitemid 351479654)
62. Ahn SM, Simpson RJ. Body fluid proteomics: prospects for biomarker discovery Prot. Clin. Appl. 1, 1004-1015 (2007).
63. Kim TH, Lee YH, Kim KH et al. Role of lung apolipoprotein A1 in idiopathic pulmonary fibrosis: anti-inflammatory and anti-fibrotic effect on experimental lung injury/fibrosis. Am. J. Respir. Crit. Care Med. 182(5), 633-642 (2010).
64. Plymoth A, Lofdahl CG, Ekberg-Jansson A et al. Human bronchoalveolar lavage: biofluid analysis with special emphasis on sample preparation. Proteomics 3(6), 962-972 (2003). (Pubitemid 36801684)
65. Lindahl M, Stahlbom B, Tagesson C. Newly identified proteins in human nasal and bronchoalveolar lavage fluids: potential biomedical and clinical applications. Electrophoresis 20(18), 3670-3676 (1999). (Pubitemid 30007265)
66. Murphy VE, Johnson RF, Wang YC et al. The effect of maternal asthma on placental and cord blood protein profiles. J. Soc. Gynecol. Investig. 12(5), 349-355 (2005). (Pubitemid 40848459)
67. Lee SH, Rhim T, Choi YS et al. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 173(4), 370-378 (2006). (Pubitemid 43228323)
68. Samter M, Beers RF. Concerning the nature of intolerance to aspirin. J. Allergy 40, 281-293 (1967).
69. Picado C. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 57(Suppl. 72), 58-60 (2002). (Pubitemid 34970039)
70. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J. 3, 588-593 (1990). (Pubitemid 20203090)
71. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br. Med. J. 1, 67-69 (1975).
72. Altman LC, Munk Z, Seltzer J et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J. Allergy Clin. Immunol. 102, 50-56 (1998). (Pubitemid 28345784)
73. Holgate ST, Sampson AP. Antileukotriene therapy. Future directions. Am. J. Respir. Crit. Care Med. 161, 147-153 (2000).
74. Cowburn AS, Sladek K, Soja J et al. Overexpression of leukotriene C(4) synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 101, 834-846 (1998). (Pubitemid 28096081)
75. Babu KS, Salvi SS. Aspirin and asthma. Chest 118(5), 1470-1476 (2000).
76. Szczeklik A, Sanak M. Genetic mechanisms in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 161(2 Pt 2), S142-S146 (2000). (Pubitemid 30129433)
77. Rhim T, Choi YS, Nam BY et al. Plasma protein profiles in early asthmatic responses to inhalation allergen challenge. Allergy 64(1), 47-54 (2009).
78. Rottoli P, Bargagli E, Landi C, Magi B. Proteomic analysis in interstitial lung diseases: a review. Curr. Opin. Pulm. Med. 15(5), 470-478 (2009).
79. Bell DY, Hook GE. Pulmonary alveolar proteinosis: analysis of airway and alveolar proteins. Am. Rev. Respir. Dis. 119(6), 979-990 (1979). (Pubitemid 9208253)
80. Wattiez R, Hermans C, Bernard A, Lesur O, Falmagne P. Human bronchoalveolar lavage fluid: two-dimensional gel electrophoresis, amino acid microsequencing and identification of major proteins. Electrophoresis 20(7), 1634-1645 (1999). (Pubitemid 29300015)
81. Chung YW, Oh HY, Kim JY et al. Allergen-induced proteolytic cleavage of annexin-1 and activation of cytosolic phospholipase A2 in the lungs of a mouse model of asthma. Proteomics 4(11), 3328-3334 (2004).
82. Greenlee KJ, Corry DB, Engler DA et al. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J. Immunol. 177(10), 7312-7321 (2006). (Pubitemid 44715101)
83. Ghosh S, Janocha AJ, Aronica MA et al. Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation. J. Immunol. 176(9), 5587-5597 (2006).
84. Kim K, Kwon J, Oh SH et al. Modulation of group-specific component blocks airway responses in an animal model of asthma by modulating the transition between Th1 and Th2. Am. J. Respir. Crit. Care Med. (In press) (2010).
85. Kelly M, Leigh R, Hargreave FE. Validation of assays for inflammatory mediators in sputum. Eur. Respir. J. 16(6), 1208-1209 (2000). (Pubitemid 32148140)
86. Nicholas B, Djukanovia R. Induced sputum: a window to lung pathology. Biochem. Soc. Trans. 37(Pt 4), 868-872 (2009).
87. Nicholas B, Skipp P, Mould R et al. Shotgun proteomic analysis of human-induced sputum Proteomics 6(15), 4390-4401 (2006). (Pubitemid 44277040)
88. Gray RD, MacGregor G, Noble D et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am. J. Respir. Crit. Care Med. 178(5), 444-452 (2008).